// App-Quantinova.ai

1074 : Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).

Researchers

Presenter

  • Robert Wesolowski

Principal Investigators

  • Susan Michelle Geyer

  • Andrea Camp

  • Jeffrey J. Chalmers

  • Eleni Andreopoulou

  • Miguel Angel Villalona-Calero

  • Charles L. Shapiro

  • Michael V. Knopp

  • Michael R. Grever

  • Rachel M. Layman

  • Erin Macrae Macrae

  • Jun Zhang

  • Nathan Hall

  • Katharina Schregel

  • Susan Ottman

  • Bhuvaneswari Ramaswamy

  • Maryam B. Lustberg

  • Ewa Mrozek

Medical Centers

  • The Ohio State Univerisity, Columbus, OH

  • Ohio State University Wexner Medical Center, Columbus, OHThe Breast Program, The Ohio State University Comprehensive Cancer Center and the Stefanie Spielman Comprehensive Breast Center, Columbus, OHOhio State University, Columbus, OH

  • The Stefanie Spielman Comprehensive Breast Center, Ohio State University Wexner Medical Center, Columbus, OH

  • Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

  • The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Richard J. Solove Research Institute, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Fanconi anemia

  • Solid malignancies

  • Anemia

  • Triple-negative breast cancer

Biomarkers

  • 18F-fluorodeoxyglucose

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Carboplatin

  • Veliparib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01251874

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved